| Overview |
| bsm-62958r-cy5-100ul |
| PKC Recombinant Monoclonal Antibody, Cy5 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PKC |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5582 |
| P05129,P05771, P17252,Q02156,Q05513,Q05655 |
| Cytoplasm, Cell membrane |
| PKC alpha; PKC beta; PKC delta; PKC epsilon; PKC gamma; PKC zeta; PKC-A; PKC-alpha; PKC2; PKCA; PKCB; PKCD; PKCE; PKCG; PRKCA; PRKCB; PRKCB1; PRKCB2; PRKCD; PRKCE; PRKCG; PRKCZ; Protein kinase C alpha; Protein kinase C alpha type; Protein kinase C; Protein kinase C beta; Protein kinase C delta; Protein kinase C epsilon; Protein kinase C gamma; Protein kinase C zeta. |
| Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues, such as regulation of the neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1, modulation of receptors and neuronal functions related to sensitivity to opiates, pain and alcohol, mediation of synaptic function and cell survival after ischemia, and inhibition of gap junction activity after oxidative stress. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz